Neuroprotective effect of SGLT2 inhibitors.
Open accessThe DOI matches its Crossref record; 122 of the 124 references it cites were found in a registry or an index; 21 of the 97 sources its claims cite were checked for support.
Abstract
Patients with diabetes are at higher risk of cardiovascular diseases and cognitive impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Sotagliflozin) are newer hypoglycemic agents with many pleiotropic effects. In this review, we discuss their neuroprotective potential. SGLT2 inhibitors (SGLT2i) are lipid-soluble and reach the brain/serum ratio from 0.3 to 0.5. SGLT receptors are present in the central nervous system (CNS). Flozins are not fully SGLT2-selective and have an affinity for the SGLT1 receptor, which is associated with protection against ischemia/reperfusion brain damage. SGLT2i show an anti-inflammatory and anti-atherosclerotic effect, including reduction of proinflammatory cytokines, M2 macrophage polarization, JAK2/STAT1 and NLRP3 inflammasome inhibition, as well as cIMT regression. They also mitigate oxidative stress. SGLT2i improve endothelial function, prevent remodeling and exert a protective effect on the neurovascular unit, blood-brain barrier, pericytes, astrocytes, microglia, and oligodendrocytes. Flozins are also able to inhibit AChE, which contributes to cognitive improvement. Empagliflozin significantly increases the level of cerebral BDNF, which modulates neurotransmission and ensures growth, survival, and plasticity of neurons. Moreover, they may be able to restore the circadian rhythm of mTOR activation, which is quite a novel finding in the field of research on metabolic diseases and cognitive impairment. SGLT2i have a great potential to protect against atherosclerosis and cognitive impairment in patients with type 2 diabetes mellitus.
Overview
CoChat Summary
TL;DR
This narrative review summarizes proposed neuroprotective mechanisms of SGLT2 inhibitors in type 2 diabetes, atherosclerosis, and cognitive impairment, including anti-inflammatory, antioxidant, anti-atherosclerotic, AChE-inhibiting, BDNF-increasing, and mTOR-rhythm-restoring effects. It concludes that flozins have potential but that long-term clinical trials are needed to establish clinical relevance.
Key findings
- SGLT2 inhibitors are lipid-soluble and cross the blood-brain barrier, with brain/serum AUC ratios of 0.3 for canagliflozin and dapagliflozin and 0.5 for empagliflozin; SGLT1/SGLT2 are expressed in the CNS, and SGLT1 inhibition is linked to protection against ischemia/reperfusion brain damage.
- Anti-inflammatory and anti-atherosclerotic effects include reduced proinflammatory cytokines, M2 macrophage polarization, JAK2/STAT1 and NLRP3 inflammasome inhibition, and cIMT regression; empagliflozin reduced cIMT by 7.9% (p < 0.0001) after 3 months, and canagliflozin lowered IL-6 by 26.6% (p = 0.010) after 2 years.
- AChE inhibition may contribute to cognitive improvement: canagliflozin Ki = 0.12859 µM with estimated brain concentration ~3 µM, enough to inhibit AChE; empagliflozin Ki = 0.177 µM with brain concentration 0.5 µM, also enough; dapagliflozin Ki = 25.02 µM with brain concentration 0.3 µM, not enough.
- Empagliflozin significantly increased cerebral BDNF in db/db mice and improved cognition; in rat cerebral ischemia/reperfusion, empagliflozin dose-dependently reduced neuronal death, infarct size, and cognitive impairment via HIF-1α/VEGF signaling; SGLT2i may restore circadian mTOR activation and mimic fasting.
Methods
- Narrative review; no primary data collection or systematic search strategy is described.
- Evidence synthesized includes preclinical studies (murine/rat models, ex vivo, in silico) and selected clinical studies on SGLT2 inhibitors, atherosclerosis, inflammation, oxidative stress, mTOR signaling, cerebrovascular dysfunction, and Alzheimer’s disease pathology.
- Main analysis is a qualitative synthesis of mechanisms and reported outcomes, with one ongoing clinical trial noted: dapagliflozin in Alzheimer’s disease (NCT03801642).
Limitations
- The paper states that long-term clinical trials are necessary to establish whether the discussed mechanisms are clinically relevant, since atheroprotective and neuroprotective effects will not be immediate and require long-term SGLT2i intake.
- The paper notes that there is no available data on adverse CNS effects of flozins and that the exact mechanism of cardiovascular benefit has not been fully established.
- Evident from the text: this is a narrative review without systematic methods, and many key findings come from animal, ex vivo, or in silico studies, with limited human cognitive-outcome data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
14 Valid · 1 Not valid · 67 Not checked · 11 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Canagliflozin, Dapagliflozin, Sotagliflozin significantly decrease the composed primary end-point, including cardiovascular mortality and other cardiovascular outcomes [10,11,12].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 1. Introduction
What the sources say
- Supportedcites [10] Mahaffey, 2018, Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study), Circulation source
The Methods (Outcomes) define the composite endpoint as cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke. The Results report that canagliflozin significantly reduced that endpoint versus placebo (P=0.02 for superiority). In this sentence with three citations, this source supports the canagliflozin portion; it is not offered as evidence for the other two drugs. (LLM, conf=0.93)
- Partly supportedcites [11] Wiviott, 2019, Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
The Cardiovascular and Renal Outcomes section reports that dapagliflozin significantly reduced the composite of cardiovascular death or hospitalization for heart failure. It also says the reduction was driven by fewer heart-failure hospitalizations, with no difference in cardiovascular death; MACE was not significantly reduced. This paper tests dapagliflozin, not the other two drugs named alongside it. Page numbers were not supplied in the passages. (LLM, conf=0.89)
- Supportedcites [12] Bhatt, 2021, Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure, N. Engl. J. Med. source
The Methods (p. 2) define the sotagliflozin trial’s composite primary endpoint as cardiovascular death, heart-failure hospitalization, and urgent heart-failure visits. The Efficacy End Points (p. 7) report a significantly lower rate for that composite with sotagliflozin than with placebo (hazard ratio 0.67; P<0.001). This source supports the sotagliflozin portion of the multi-citation sentence; it does not establish a significant reduction in cardiovascular death on its own. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SGLT1 inhibitors are present in the pyramidal cells of the brain cortex, Purkinje cerebellum cells, hippocampus pyramidal, and granular cells [20].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 2. Neurological Potential of SGLT2 Inhibitors
What the sources say
- Partly supportedcites [20] Poppe, 1997, Expression of the Na+-D-glucose cotransporter SGLT1 in neurons, J. Neurochem. sourceExperimental — accuracy not yet measured
The 'Expression of SGLT1 protein in brain' section and Fig. 7 report SGLT1 protein in cortical pyramidal cells, hippocampal pyramidal and granular cells, and cerebellar Purkinje cells. The citing sentence says 'SGLT1 inhibitors' are present; these passages identify the protein, not inhibitors. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Among commonly used SGLT2 inhibitors, Canagliflozin has the greatest potential for inhibiting SGLT1 receptors.”
§ Neuroprotective Effect of SGLT2 Inhibitors > 2. Neurological Potential of SGLT2 Inhibitors
What the sources say
- Could not verifycites [27] Malhotra, 2015, Sodium glucose co-transporter inhibitors—A new class of old drugs, Int. J. Appl. Basic Med. Res. sourceExperimental — accuracy not yet measured
Our copy names canagliflozin only as 'the prototype drug among the newer agents' with its pharmacokinetics (PHARMACOKINETICS section), and it discusses SGLT-1/SGLT-2 selectivity in general terms (INTRODUCTION, HISTORICAL BACKGROUND, 'On fasting hypoglycemia'), but nowhere states that canagliflozin has the greatest SGLT-1 inhibitory potential among the SGLT2 inhibitors. The one place that could carry it — 'Table 1 New SGLT inhibitors and their status and selectivity' — appears in our copy only as a caption, with no table rows/indexed content, so the comparative selectivity data are not available to us. Searches for 'canagliflozin SGLT1 selectivity', 'selectivity ratio SGLT-1 versus SGLT-2 / IC50', 'Table 1 status and selectivity', and 'SGLT-1 inhibition adverse effects' returned no passage making or contradicting the claim. (LLM, conf=0.65)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In humans, the serum level of IL-6 dropped by 26.6% (p = 0.010) after 2 years of canagliflozin treatment [35].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 4. Inflammation
What the sources say
- Partly supportedcites [35] Heerspink, 2019, Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease, Diabetologia sourceExperimental — accuracy not yet measured
The Abstract (Results) and Table 2 of our copy do carry the exact figure: canagliflozin 300 mg/day lowered IL-6 by 26.6% (95% CI −42.0, −7.2), p = 0.010, over 2 years (104 weeks) — but explicitly as a least-squares mean percentage DIFFERENCE VERSUS GLIMEPIRIDE and only at the 300 mg dose (100 mg gave −26.3%, p = 0.011), in people with type 2 diabetes and elevated albuminuria (CANTATA-D/SU subset, n = 296). The citing sentence recasts this between-group contrast as an absolute 'drop' of 26.6% from canagliflozin treatment alone, and drops both the comparator and the dose qualifiers. It also says 'serum', whereas the Methods (Biomarker measurement) state IL-6 was measured by Luminex assay on stored PLASMA samples. The magnitude, p value and 2-year duration are faithful; the attribution of the 26.6% as a within-treatment fall in serum is not supported. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In previous studies, atherosclerotic lesions in intra- and extra-cranial arteries were associated with cognitive impairment and even dementia [2,66,67].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 3. Atherosclerosis, Cognitive Impairment, and SGLT2i
What the sources say
- Not checked yetcites [2] Dearborn, 2017, Intracranial atherosclerosis and dementia The Atherosclerosis Risk in Communities (ARIC) Study, Am. Acad. Neurol.
- Supportedcites [66] Bos, 2015, Atherosclerotic calcification is related to a higher risk of dementia and cognitive decline, Alzheimer’s Dement. source
The Results section reports that after censoring for stroke, 'both extracranial and intracranial carotid artery calcification remained statistically significantly associated with dementia' (HR 1.32 and 1.34 per SD increase), and that larger calcification volumes were associated with cognitive decline in nondemented persons. The Abstract Conclusions and Discussion (generalized atherosclerosis 'is associated with dementia') state the same association for dementia and cognitive deterioration, matching the cited claim for both intra- and extra-cranial arteries. Minor wording differences (calcification as the atherosclerosis measure; 'cognitive decline' rather than 'cognitive impairment') do not alter the attributed content. (LLM, conf=0.88)
- Partly supportedcites [67] Wingo, 2020, Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain, Nat. Neurosci. sourceExperimental — accuracy not yet measured
The Abstract/Introduction of our copy supports the intracranial half of the claim: cerebral atherosclerosis is defined as plaques in 'the walls of large arteries in the brain' and is stated to be among the earliest changes associated with development of AD dementia, with ~three times higher risk for AD and nine times higher risk for vascular dementia (Abstract, p. 1). The METHODS confirm the paper's own atherosclerosis assessment covered only intracranial vessels — visual grading of the Circle of Willis (vertebral, basilar, posterior, middle and anterior cerebral arteries and proximal branches), not extracranial arteries (METHODS, ROS/MAP section). No passage in our copy addresses atherosclerotic lesions in extra-cranial arteries and cognition (searched: 'extracranial carotid atherosclerosis', 'carotid artery atherosclerosis systemic extracranial vessels'), so that part of the citing sentence is not supported by this source. (LLM, conf=0.72)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
42 more claims · 2 with their cited sources checked
Create a free account to see all 93 claims and to verify the 76 references still open.
- It may state two separate claims as one. 41
- Probably not a substantial claim. 6
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, SGLT2is have demonstrated neuroinflammatory and antioxidative effects in addition to cardiovascular prevention.56”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [56]
Citations
Cites
1 retracted
Xue, L., Yuan, X., Zhang, S., & Zhao, X. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9388562 · Cited by 20
RetractedEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · cited 1×
“In the CANTOS study, inhibition of interleukin-1β with canakinumab significantly reduced cardiovascular risk independently of lipid levels [78].”
BackgroundDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 1×
“The exact mechanism has not been fully established yet, and SGLT2 inhibitors show many additional beneficial effects which contribute to their wider use, even in non-diabetic patients [14].”
BackgroundReactive Oxygen Species in Inflammation and Tissue Injury
Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P., & Malik, A. B. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5149 · Cited by 4,897 · cited 4×
“The overproduction of ROS or decrease in the anti-oxidant defense results in oxidative stress, which is a significant contributor to vascular diseases, including atherosclerosis, as it causes endothelial dysfunction, promotes remodeling and further enhances inflammation [94].”
BackgroundInfluentialO'Leary, D. H., Polak, J. F., Kronmal, R. A., Manolio, T. A., Burke, G. L., & Wolfson, S. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400103 · Cited by 4,685
The NLRP3 Inflammasome: an overview of mechanisms of activation and regulation
Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133328 · Cited by 3,539 · cited 1×
“It is a crucial element of the innate immune system activated not only by microbial infection or cellular damage but also by chronic inflammatory diseases, including atherosclerosis and Alzheimer’s disease [80].”
BackgroundEinarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease causing a variety of complications, including atherosclerosis which is associated with increased cardiovascular risk contributing to reduced life expectancy [1].”
BackgroundSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868 · cited 1×
“It is even called a “dual SGLT1/SGLT2 inhibitor”, however, it is the newest Flozin, and it is not yet used in diabetic patients on a large scale [12].”
Background
Research works printed but not linked: 1
- Esterline, R., Oscarsson, J., and Burns, J. (2020). International Review of Neurobiology, Elsevier Inc.. [1st ed.].
Cited by
Items 101–200 of 326
Riemma, M. A., Mele, E., Donniacuo, M., Telesca, M., Bellocchio, G., Castaldo, G., Rossi, F., Angelis, A. D., Cappetta, D., Urbanek, K., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1422740 · Cited by 14
“SGLT1 is localized in the pyramidal cells of the brain cortex, Purkinje cerebellum cells, hippocampus pyramidal, and granular cells (Pawlos et al., 2021).”
Miceli, G., Basso, M. G., Pennacchio, A. R., Cocciola, E., Pintus, C., Cuffaro, M., Profita, M., Rizzo, G., Sferruzza, M., & Tuttolomondo, A. (2024) · Medicina · doi:10.3390/medicina60111796 · Cited by 14
Davri, A. S., Katsenos, A. P., Tulyaganova, G. K., Tzavellas, N. P., Simos, Y. V., Kanellos, F. S., Konitsiotis, S., Dounousi, E. C., Niaka, K., Bellou, S., et al. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01478-6 · Cited by 14
“It has been shown that SGLT2i have the molecular ability to inhibit acetylcholinesterase and increase brain-derived neurotrophic factor (BDNF), which plays an important role in neuronal survival and growth, and participates in neuronal plasticity (Pawlos et al. 2021).”
Li, S., Yu, N., Xu, F., Yu, L., Yu, Q., & Fu, J. (2022) · Journal of Ginseng Research · doi:10.1016/j.jgr.2022.05.006 · Cited by 13
“Although these SLC5A2 inhibitors had higher affinities to SLC5A2 compared to SLC5A1, they still bind to SLC5A1 [39].”
BackgroundBarilar, J. O., Perhoč, A. B., Knezović, A., Homolak, J., Virag, D., & Šalković‐Petrišić, M. (2023) · Biomedicines · doi:10.3390/biomedicines11041025 · Cited by 12
“There are only a few clinical studies investigating this effect which showed highly inconsistent results, and some of them showed no positive effect of SGLT2 inhibitors on cognitive functions [7,8].”
BackgroundResultTranslational research on cognitive impairment in chronic kidney disease
Wagner, C. A., Massy, Z. A., Capasso, G., Mattace-Raso, F., Pépin, M., Bobot, M., Zoccali, C., Ferreira, A. C., Hoorn, E. J., Silva, P. H. I., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae229 · Cited by 16
Abdelhafez, G. F., Boshra, S. A., Abo-Zalam, H. B., & Radwan, S. M. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04538-0 · Cited by 13
“…blood–brain barrier (BBB), it can cause substantial neurotoxicity with neuronal and synaptic loss, prompting cognitive deficits in the brain [39, 42 ] In the current work, DOX-induced oxidative stress was proved by higher levels of NOX4 and MDA, accompanied by loss of antioxidant defense…”
Osman, A., Kanaan, A., Azeroual, S., Abubakr, M., Jwayyed, J. S., & Bhutta, R. (2025) · Cureus · doi:10.7759/cureus.92760 · Cited by 15
“For example, one study in this area showed that vascular stretch and shear stress in the setting of chronic hypertension led to paracellular leakage, perivascular inflammation, and white matter rarefaction [36].”
Rewinding the Clock: Emerging Pharmacological Strategies for Human Anti-Aging Therapy
Delrue, C., Speeckaert, R., & Speeckaert, M. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199372 · Cited by 14
“Further, there is emerging evidence to suggest potential neuroprotective actions, including the reduction in neuroinflammation, improvement in synaptic plasticity, and improvement in neurotrophic factor signaling, which may be relevant to age-associated cognitive decline [73–80].”
Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy
Colbert, G. B., Madariaga, H. M., Gaddy, A. R., Elrggal, M. E., & Lerma, E. V. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s398163 · Cited by 12
“Further studies looking at Alzheimer’s research is ongoing to see how empagliflozin and other SGTL2i class drugs alter inflammation, oxidative stress, neurotransmitter imbalance, and synaptic loss.(34) Further clinical trials are discussed in Table 1.”
BackgroundLiu, T., Lin, Y., Yu, T., Wu, J., & Lai, C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112197 · Cited by 11
Han, J., Song, J., Jung, E. S., Choi, J. W., Ji, H. Y., & Mook‐Jung, I. (2025) · Aging Cell · doi:10.1111/acel.70101 · Cited by 11
“These include improvements in cognitive functions in diabetic mouse models, reduction of oxidative stress and neuroinflammation, and enhancement of neuronal plasticity and mitochondrial function in the brain (Pawlos et al. 2021; Rizzo et al. 2022).”
Targeting Neurodegeneration with SGLT2is: From Molecular Mechanisms to Clinical Implications
Asadinejad, H., Taherkhani, S., Golboos, S. M., Azizi, Y., & Mohammadkhanizadeh, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05457-5 · Cited by 11
Hsu, S., Huang, H., Pun, C. K., Chang, C.-C., Chuang, C., Huang, Y., Hou, M., & Lee, F. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001289 · Cited by 11
“Emerging reports show that SGLT-2 inhibitors protect neuro-vascular units (Pawlos et al., 2021).”
BackgroundLondzin, P., Brudnowska, A., Kurkowska, K., Wilk, K., Olszewska, K., Ziembiński, Ł., Janas, A., Cegieła, U., & Folwarczna, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113679 · Cited by 11
The Impact of Pharmacotherapy for Heart Failure on Oxidative Stress—Role of New Drugs, Flozins
Bodnar, P., Mazurkiewicz, M., Chwalba, T., Romuk, E. B., Ciszek-Chwalba, A., Jacheć, W., & Wojciechowska, C. (2023) · Biomedicines · doi:10.3390/biomedicines11082236 · Cited by 12
“The effects of SGLT2 inhibitors, such as reduced gluconeogenesis, improved insulin sensitivity, increased cellular response to glucagon, stimulated insulin release from pancreatic beta cells, and improved tissue sensitivity to insulin, promote an anti-atherosclerotic effect, resulting in protection of the kidneys, myo…”
BackgroundRamakrishan, P., Rajangam, J., Mahinoor, S. S., Bisht, S., Mekala, S., Upadhyay, D. K., Solomon, V. R., Sabarees, G., & Pelluri, R. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01555-4 · Cited by 11
“By blocking mTOR, these inhibitors can stop the development of pathology associated with AD and restore mTOR signalling (Pawlos et al. 2021).”
Tang, H., Donahoo, W. T., DeKosky, S. T., Lee, Y. A., Svensson, M., Bian, J., & Guo, J. S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70161 · Cited by 11
Kamel, A. S. E. D., Farrag, S. M., Mansour, H. M., Nassar, N. N., & Saad, M. A. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2206955 · Cited by 12
Borikar, S. P., Sonawane, D. S., Tapre, D. N., & Jain, S. P. (2024) · International Journal of Neuroscience · doi:10.1080/00207454.2024.2342973 · Cited by 12
“Notably expression of SGLT2 extensively found in the hippocampus, amygdala, hypothalamus, periaqueductal grey (PAG), and in the dorsomedial medulla—the nucleus of the solitary tract (NTS) and which may highlight the impending therapeutic role in brain injury [18,19].”
Nasr, M. M., Wahdan, S. A., El‐Naga, R. N., & Salama, R. M. (2024) · NeuroToxicology · doi:10.1016/j.neuro.2024.10.006 · Cited by 11
The Mechanism and Treatment of Cognitive Dysfunction in Diabetes: A Review
Hou, Y., Chen, Z., Cheng, J., Li, G., Yin, L., & Gao, J. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2480-7826 · Cited by 10
“SGLT2 inhibitors are relatively new hypoglycemic agents with anti-inflammatory properties that increase macrophage polarization, inhibit NLRP3 inflammasome activation [84], and ameliorate cog - nitive dysfunction [85].”
İmeci, O. B., Asci, H., Aşcı, S., Sevük, M. A., Sarikaya, H. S., & Ozmen, O. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177913 · Cited by 9
Jain, S., Acharya, R., Verma, L., & Chauhan, A. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00077 · Cited by 11
Kaur, R., Singh, S., Sood, P., Singh, S., Banerjee, S., & Singh, T. G. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10562-7 · Cited by 9
Lin, T., Chen, Y.-H., Huang, J., Liao, P., Chen, M., Pan, L.-F., & Jong, G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.966708 · Cited by 9
He, S., Yu, Y., Chen, P.-Q., Sun, H., Gao, X., Sun, H., & Ge, J. (2024) · Journal of Diabetes Research · doi:10.1155/2024/5661751 · Cited by 9
Liu, J., Shi, X., & Shao, Y. (2024) · Brain and Behavior · doi:10.1002/brb3.3624 · Cited by 10
“Preclinical experiments have shown that these medications can improve brain energetics (Pawlos et al., 2021), andarecentrandomizedcontrolledtrialdemonstratedimprovedmood outcomes with the selective SGLT2 inhibitor empagliflozin in combination with citalopram (Zandifar et al., 2024).”
BackgroundAnoush, M., Taghaddosi, N., Hosseini, Z. B., Rahmati, F., Bijani, S., Kalantari‐Hesari, A., & Hosseini, M. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.01.008 · Cited by 12
Xu, B., Yang, M., Li, S., Kang, B., & Zhou, J. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251317495 · Cited by 9
Zeng, X., Yuan, Y., Li, Y., Hu, Z., & Hu, S. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115304 · Cited by 8
Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors
Chrysant, S. G., & Chrysant, G. S. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2057949 · Cited by 8
“easy the blood-brain barrier and directly affect their target, since SGLT1 and SGLT2 receptors are expressed in the human central nervous system and play an important role in maintaining glucose homeostasis [30].”
BackgroundInfluentialHsu, M., Luo, K.-S., Chou, C., Lin, Y., Hung, Y.-C., Chuang, W.-L., Tsai, S. C., Lin, H.-J., Yu, T., Tsai, F., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02303-3 · Cited by 8
Zhang, S., Wang, F., Xie, L., Xu, J., Song, X., Tao, J., Chen, J., Ma, D., Yu, X., Shi, X., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14306 · Cited by 8
“The neuroprotective effects of SGLT2is could also involve reduced in fl ammation, M2 polarization, Janus kinase 2/signal transducer and activator of transcription 1 and NOD-, LRR-and pyrin domain-containing protein 3 in fl ammasome inhibition, and a reduction in carotid intima-media thickness 36 .”
Borikar, S. P., Chitode, G. V., Tapre, D. N., Lokwani, D. K., & Jain, S. P. (2024) · International Journal of Neuroscience · doi:10.1080/00207454.2024.2414270 · Cited by 10
“…2 inhibitors (sGlt2i) are novel class of antidiabetic drugs, more lipid-soluble and reach the brain/serum ratio ranges from 0.3 to 0.5 [9]. in the earlier research it is found that sGlt2 densely expressed in the frontal cortex, hippocampus, caudate nucleus, putamen, parietal cortex,…”
InfluentialMurasheva, A., Fuks, O., Тимкина, Н. В., Mikhailova, A., Vlasov, T. D., Samochernykh, K. A., & Каронова, Т. Л. (2024) · Biomedicines · doi:10.3390/biomedicines12122797 · Cited by 8
Cognitive Benefits of Sodium-Glucose Co-Transporters-2 Inhibitors in the Diabetic Milieu
Yaribeygi, H., Maleki, M., Sathyapalan, T., Rizzo, M., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230202163513 · Cited by 10
Chang, E.-W., Huang, J., Lo, S., Huang, C., Yang, Y., & Kornelius, E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1601118 · Cited by 7
Das, B. B. (2024) · Medicina · doi:10.3390/medicina60071112 · Cited by 8
“SGLT2 inhibitors (SGLT2is), such as Dapagliflozin and Empagliflozin, exhibit a higher affinity for SGLT2 over SGLT1, influencing their therapeutic effects [61].”
BackgroundСиманенкова, А. В., Fuks, O., Тимкина, Н. В., Islamova, A., Суфиева, Д. А., Kirik, O. V., Korzhevsky, D. E., Vlasov, T. D., & Каронова, Т. Л. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2907265 · Cited by 7
Zhang, Y., Liao, X., Xu, J., Yin, J., Li, S., Li, M., Shi, X., Zhang, S., Li, C., Xu, W., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12122783 · Cited by 7
Sarabhai, T., Zingel, R., Bohlken, J., & Kostev, K. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112430 · Cited by 7
Zheng, Z., Chen, X., Zhang, Y., Zhang, Y., Wang, K., Shi, Z., Yang, X., Yuan, F., & Liu, J. (2023) · Neurotherapeutics · doi:10.1016/j.neurot.2023.11.002 · Cited by 7
“Currently, canagli fl ozin, empagli fl ozin, dapagli fl ozin and ertu-gli fl ozin were widely used as the SGLT2 inhibitors and they can cross the blood-brain barrier [6].”
BackgroundChiang, P.-C., Hsieh, C., & Sung, S. (2025) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2025.108276 · Cited by 7
“This order aligns with the potency of AChE inhibition among these three molecules, with canagliflozin showing the highest potency, followed by empagliflozin and dapagli-flozin, 37 thereby providing biological plausibility to our findings.”
Empagliflozin Protects Against Oxidative Stress in the Diabetic Brain by Inducing H2S Formation
Özbek, E. N., Yeşilyurt, Z. E., Makal, M., Arioglu‐Inan, E., & Yetik-Anacak, G. (2025) · Pharmaceuticals · doi:10.3390/ph18091259 · Cited by 6
“SGLT2 inhibitors are lipid-soluble drugs that cross the blood–brain barrier and exert neuroprotective effects in the brain [35].”
Amawi, H. A., Alsheyab, S., Hammad, A. M., Alhazaimeh, R., Maklouf, T., Al‐Trad, B., Almarghalani, D. A., Alzahrani, M. S., Ashby, C. R., & Tiwari, A. K. (2025) · Genes Brain & Behavior · doi:10.1111/gbb.70037 · Cited by 6
Țucă, A.-M., Preda, A. N., Târtea, G. C., Hădăreanu, D.-R., Țieranu, E. N., Dan, A. O., Târtea, E. A., Greșiță, A., Pîrșcoveanu, D. F. V., Sfredel, V., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412034 · Cited by 6
“In recent years, attention has focused on the potential neuroprotective role of SGLT2 inhibitors in diabetes in the context of reducing oxidative stress, inflammation, and fibrogenesis [65–68].”
Liu, Y., Fang, C., Chen, C., Yu, Y., Wang, J., Ye, L., Zhang, C., & Feng, Z. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.12.059 · Cited by 6
Симаненкова, А. В., Станиславовна, Ф. О., Тимкина, Н. В., Суфиева, Д. А., Kirik, O. V., Korzhevsky, D. E., Vlasov, T. D., & Каронова, Т. Л. (2024) · Problems of Endocrinology · doi:10.14341/probl13336 · Cited by 6
“…иНГЛТ-2 за счет дополнительной супрессии на-трий-глюкозного котранспортера 1 типа, в том числе в головном мозге, что, в свою очередь, приводит к умень-шению ишемического-реперфузионного повреждения и ограничению очага некроза, а также снижению выра-женности асептического воспаления [10].”
Reducing Alzheimer’s disease risk with SGLT2 inhibitors: From glycemic control to neuroprotection
Alami, M., Morvaridzadeh, M., Khayari, A. E., Boumezough, K., Fatimy, R. E., Khalil, A., Fülöp, T., & Berrougui, H. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102751 · Cited by 6
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2025) · Diabetes Care · doi:10.2337/dc25-0433 · Cited by 6
Molecular Biomarkers and Therapeutic Approach of Patients with Diabetes and Obstructive Sleep Apnea
Elian, V., Popovici, V., Steriade, A. T., Radulian, G., Ozon, E. A., Moroșan, E., & Muşat, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010234 · Cited by 6
Симаненкова, А. В., Станиславовна, Ф. О., Тимкина, Н. В., Каронова, Т. Л., Цыба, Д. Л., Kirik, O. V., Korzhevsky, D. E., & Vlasov, T. D. (2022) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093022050234 · Cited by 6
“However, the prerequisites for such an effect of this class of glucose lowering drugs are available and might be due to their broad protec tive profile for the cardiovascular system, as well as the expression of the sodium–glucose co trans porter of both types (I and II) in the brain tissue and vascular endothelium [9…”
BackgroundSodium-glucose cotransporter-2 inhibitors: A potential novel treatment for Lafora disease?
Imbrici, P., d’Orsi, G., Carella, M., Nicolotti, O., Luca, A. D., Altomare, C., & Liantonio, A. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107012 · Cited by 6
Yang, P., Wang, P.-H., Huang, J., Lee, C., Lin, C.-W., Lee, C., & Yang, S. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.95584 · Cited by 6
“Moreover, the application of SGLT2 inhibitors correlates to neuroprotective consequences which may be considered for cognitive impairment therapy [9].”
BackgroundRizk, S. K., Ali, E., Sheref, A. A. M., Tayel, S. G., & Derbaly, S. A. E. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2481849 · Cited by 7
“SGLT2 inhibitors exhibit different beneficial effects other than the antidiabetic effect, and this accounts for its wide use [29].”
Fatima, E., Irfan, H., Fatima, F., Jain, J., Rehman, O. U., Sehar, A., Ahmad, B., Kumari, S., & Akilimali, A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003357 · Cited by 6
“In addition to diabetic and cardiovascular effects, recent literature has shown that SGLT2 inhibitors and sotagliflozin also have neuroprotective effects [62] .”
Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?
Hummel, J. R., Kullmann, S., & Heni, M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac179 · Cited by 6
Empagliflozin effects on cyclophosphamide-induced neurotoxicity in rats without diabetes
Doğan, Ş. E., Kuşkonmaz, Ş. M., Çelepli, P., Şeneş, M., Hücümenoğlu, S., & Çulha, C. (2025) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5943 · Cited by 5
“These agents are not wholly SGLT2 selective and have an affinity for SGLT1 [1].”
Li, J., Wang, X., Zheng, Q., Tian, J., Chen, H., & Yao, S. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04952-w · Cited by 7
“In addition, Pawlos et al. also found SGLT2i can protect nerves by inhibiting acetylcholine esterase or increasing brain-derived neurotrophic factor [45].”
Abouzaid, H. H., El-Yamany, M. F., Mosaad, Y. O., Sayed‐Ahmed, M. M., Karkeet, R. M., & El-Sahar, A. E. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01681-z · Cited by 5
“Furthermore, DAPA could repair the circadian rhythm of mTOR activation (Nguyen et al. 2020 ; Pawlos et al. 2021 ).”
Abdel-Rahman, R. F., Alsugoor, M. H., Alsuhaymi, N., Fayed, H. M., Mahmoud, S. S., Ibrahim, F. A., & Elbaset, M. A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00039-x · Cited by 5
“According to recent research, SGLT2 inhibitors reduce inflammation by specifically targeting the NLRP3 inflammasome (Pawlos et al. 2021).”
Sahoo, S. K., Paidesetty, S. K., Sahu, P. K., Pattanaik, S., & Dandela, R. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109129 · Cited by 6
Synergistic effects of GABA and hypoglycemic drugs
Tyurenkov, I. N., Faibisovich, T. I., & Bakulin, D. A. (2023) · Problems of Endocrinology · doi:10.14341/probl13257 · Cited by 5
Ishibashi, Y., Sogawa, R., Ogata, K., Matsuoka, A., Yamada, H., Murakawa‐Hirachi, T., Mizoguchi, Y., Monji, A., & Shimanoe, C. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01337-9 · Cited by 5
Chung, J.-F., Yang, P.-J., Chang, C., Lee, C., Huang, J., Wang, K., & Yang, S. (2024) · Archives of Medical Science · doi:10.5114/aoms/174228 · Cited by 5
SGLT2 inhibition mitigates intracerebral hemorrhage risk by modulating inflammation
Huang, M., Liu, Y., & Chen, C. (2025) · Scientific Reports · doi:10.1038/s41598-024-84118-4 · Cited by 5
Tang, H., Donahoo, W. T., DeKosky, S. T., Lee, Y. A., Kotecha, P., Svensson, M., Bian, J., & Guo, J. S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70313 · Cited by 5
SGLT2 inhibitors vs. metformin for Parkinson's disease risk reduction in type 2 diabetes
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251359391 · Cited by 5
Matuszewski, W., Tomaszek, L., Szklarz, M., Górny, J. M., Kordas, B., Rutkowska, J., & Juranek, J. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186348 · Cited by 4
“These compounds are lipid-soluble and achieve a brain-to-serum ratio of 0.3 to 0.5, allowing them to cross the blood–brain barrier and act directly in the central nervous system [35].”
InfluentialYeh, T., Wu, Y., Lin, Y., Sun, G., Tseng, C.-J., & Cheng, P. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117435 · Cited by 4
Milori, P. H., Armelin, L. M., Mutarelli², A. M., & Caramelli, P. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251395086 · Cited by 5
“9 Cerebral atherosclerosis has been associated with cognitive decline and dementia.”
Association of SGLT2 inhibitors and new-onset dementia in non-diabetic patients with heart failure
Hacil, A., Piccoli, M., Antakly, Y., Guglieri, M., Lochon, L., Duneton, S., Hanon, O., & Fauchier, L. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag038 · Cited by 4
Yang, W., Yang, Q., Wang, Z., Zhao, X., Deng, J., Xia, X., Wang, J., Xia, L., Wang, Y., Cui, F., et al. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004179 · Cited by 7
“These microve-sicles enter the circulation, compromise the BBB, [144] and facilitate the entry of inflammatory mediators into the periphery.”
Longo, M., Caruso, P., Scappaticcio, L., Maiorino, M. I., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15451 · Cited by 4
“32 All these factors may influence vascular health and CIMT.”
BackgroundDing, J., Zou, L., Xu, R., Dong, L., Wang, S., Liu, N., Zhang, D., Du, Y., Pan, T., & Zhong, X. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177819 · Cited by 5
Yao, Y.-P., Yang, P., Lee, C., Huang, J., Yang, S., & Lin, H. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.88720 · Cited by 4
“Beyond blood sugar control, SGLT2 inhibitors have protective effects on various systemic diseases and neoplasms [18-20].”
BackgroundVieira, A. B., Cavanaugh, S. M., Ciambarella, B. T., & Machado, M. V. R. (2025) · Frontiers in Veterinary Science · doi:10.3389/fvets.2025.1480977 · Cited by 4
Wang, M., Guan, X., Yan, J., Michael, N. A., Liu, X., Tan, R., Lv, X., Yan, F., & Cao, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1076030 · Cited by 4
Tsai, T.-Y., Yang, P., Chao, S.-C., Lee, C., Huang, J., Yang, S., & Lin, H. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.91571 · Cited by 4
“The SGLT2 inhibitors have demonstrated significant effect on hyperglycemia retardation and protection ability on several organs including malignancy [6, 18, 19].”
BackgroundSGLT2 inhibitors for the treatment of diabetes: a patent review (2019–23)
Baghel, R., Chhikara, N., Kumar, P., & Tamrakar, A. K. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2379929 · Cited by 6
Interdisciplinary Engagement In Neurocardiology: A Key Opportunity
Lusk, J. B., Grory, B. M., Sheth, K. N., & Bhatt, D. L. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.034804 · Cited by 4
Omari, M. B., Naseri, S., & Hassan, A. J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s448670 · Cited by 3
“126 Based on the location of these receptors, the ability of SGLT2 inhibitors to pass, and their modulatory effects on their receptors, these drugs have neural effects.”
BackgroundNg, P. Y., Ng, A. K., Ip, A., Sin, W. C., & Yiu, K. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.037207 · Cited by 3
SGLT2 inhibition, circulating biomarkers, and Alzheimer's disease: A Mendelian randomization study
Yang, H., Ning, Y., Chen, M., & Jia, J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241309674 · Cited by 3
“33,34 Preclinical research in animal models demonstrates that SGLT2 inhibitors, speci fi cally empagli fl ozin, can decrease A β plaque accumulation, limit brain cortex atrophy, lessen neuronal loss, and improve cognitive functions in AD model mice.”
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
Арманович, А. А., Sheibani, M., Трофименко, А. И., Lysov, E. E., Khamidova, F. M., Aznauryan, A., Sukiasyan, L. M., Sahakyan, K., Gevorgyan, T. R., Tatoyan, M. R., et al. (2025) · Innovative medicine of Kuban · doi:10.35401/2541-9897-2025-10-1-101-109 · Cited by 3
Contribution of metabolism-independent glucose sensing to metabolic homeostasis
Rashid, N., & Chhabra, K. H. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.08.008 · Cited by 3
Wang, P., Liang, L., Tan, Y., Ge, Q., Huang, Z., & Yu, T. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.043523 · Cited by 3
“9,10 Of particular interest is the role of ketone bodies, such as β - hydroxybutyrate (BHB), which has gained attention as alternative energy substrates for neurons under ischemic conditions.”
Neuroprotective strategies for cognitive decline in type 2 diabetes
Cimini, F. A., Cuenca‐Royo, A., Gomis‐González, M., Forcano, L., Barchetta, I., Barone, E., Cavallo, M. G., & de la Torre, R. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.04.003 · Cited by 3
Hypoglycemic Therapy and the Course of Post-Covid Syndrome, is There a Connection?
Игнатенко, Г. А., Bagriy, A. E., Приколота, О. А., Вадимовна, П. А., & Mogilevskaya, K. E. (2023) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2023-13-2-129-135 · Cited by 3
Neuroprotective effects of glucose-lowering drugs in rat focal brain ischemia-reperfusion model
Симаненкова, А. В., Станиславовна, Ф. О., Тимкина, Н. В., Александровна, Т. П., Vlasov, T. D., & Каронова, Т. Л. (2023) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2023-29-6-579-592 · Cited by 3
Neuroprotective potential of gliflozins
Kokin, A. S., & Суплотова, Л. А. (2023) · Diabetes Mellitus · doi:10.14341/dm13085 · Cited by 3
SGLT2 Inhibitors and GLP-1 Agonists: A Beacon of Hope for Stroke Prevention in Diabetes
Jeon, J. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0079 · Cited by 3
“Furthermore, the presence of SGLT1 in the brain and its overexpression in areas of brain damage could contribute to ischemia and reperfusion injury, bolstering the argument for sotagliflozin’s unique role in stroke prevention [12].”
BackgroundFahimi, B. H. H., & Beikmohammadi, S. (2024) · African Research Journal of Medical Sciences · doi:10.62587/afrjms.1.1.2024.72-86 · Cited by 2
Tsui, T.-L., Ho, Y., Ueng, K.-C., Liao, P., Huang, J., Lee, C., Su, S., & Yang, S. (2024) · Journal of Cancer · doi:10.7150/jca.101165 · Cited by 2
“International Publisher demonstrated to have neuroprotective effects and may be applied to treat cognitive impairment [7].”
BackgroundAbdel-Lah, E. S., Hamad, N., Taha, A. F., Mohamed, W. H., Fawy, M. A., Attaai, A., Abbas, F. Y. A., Sherkawy, H. S., Abdelwarith, A. M., & Gamea, M. G. (2025) · Drug Development Research · doi:10.1002/ddr.70180 · Cited by 3
“According to Pawlos et al.(2021) and Xu et al. (2022) this impact is ascribed to their capacity to inhibit AChE as well.”
Dhureja, M., Munshi, A., & Kumar, P. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-02034-z · Cited by 2
“A pharmacokinetic study of dapagliflozin revealed that the brain-to-plasma ratios range from 0.3 to 0.5, confirming the BBB crossing and CNS-penetration ability of dapagliflozin (Pawlos et al. 2021).”
InfluentialYeh, H., Chaou, C., Yang, S.-F., Wang, Y., Kuan, Y., & Yeh, C. (2025) · Virology Journal · doi:10.1186/s12985-025-03054-5 · Cited by 2
“…also possess neuroprotective and anti-inflammatory properties within the central nervous system by modulating glial activation and restoring mitochondrial redox balance, which may mitigate cognitive impairment (“brain fog”) and neuropsychiatric manifestations such as anxiety and depression [41].”
Jhang, Y., Lu, H.-Y., LIN, C.-Y., LEE, C.-Y., Su, Y.-J., Chang, H.-C., Chen, S., & Gau, S. (2026) · In Vivo · doi:10.21873/invivo.14229 · Cited by 2
“SGLT2i directly regulates the miR ‐ 21 ‑ reversion inducing cysteine rich protein with kazal motifs (RECK) axis to inhibit the expression of MMP2 and MMP9 (45, 46).”
Chen, J., Wan, F., Wu, K., Xie, X., & WU, T. (2026) · Xenobiotica · doi:10.1080/00498254.2026.2613138 · Cited by 2
“Further research is warranted to investigate their mechanisms of action within the central nervous system (Pawlos et al. 2021).”
Metadata
- Authors
- Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P.
- Affiliations
- Medical University of Lodz (PL)
- Laboratory of Tissue Immunopharmacology, Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz, Kniaziewicza 1/5, 91-347 Lodz, Poland
- Corresponding author
- Broncel, Marlena
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-11-28
- Volume
- 26
- Issue
- 23
- Pages
- 7213
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8659196
- OpenAlex
- W3214770882
- Semantic Scholar
- d4fddd52e53127993c142ff6d31526f815eb1c00
- Cited by
- 304
- References
- 124
- Citations by year
- 2026: 66 · 2025: 92 · 2024: 71 · 2023: 50 · 2022: 25
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- SGLT2 inhibitors, neuroprotection, type 2 diabetes, cognitive impairment, cardiovascular disease, anti-inflammatory activity, NLRP3 inflammasome, cerebral blood flow, neurovascular unit, blood-brain barrier, acetylcholinesterase inhibition, brain-derived neurotrophic factor, atherosclerosis
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Brain, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Neuroprotective Agents, Atherosclerosis, Sodium-Glucose Transporter 2, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.